Home Approval

Approval

Eisai’s Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer...

Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least...

Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded...

Hyderabad, June 14, 2019: Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy's would sell its US...

Lupin’s Pithampur Unit-3 (Indore) receives EIR from USFDA

Mumbai, April 18, 2019: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) for its Pithampur (Unit-3) facility. The inspection was conducted between October 8, 2018 to October 18, 2018. Lupin’s Pithampur Unit-3 is involved...